University of California at San Francisco (UCSF)
Welcome,         Profile    Billing    Logout  
 11 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roberts, John R
NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Active, not recruiting
1/2
780
US
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo, Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA, Phase 2 selected SARS-CoV-2 mRNA
GlaxoSmithKline
COVID-19
05/25
11/25
NCT06702449: A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Recruiting
1/2
448
Europe, US, RoW
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
GlaxoSmithKline
Urinary Tract Infections
08/27
08/27
NCT04740879: The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms

Completed
N/A
137
US
Be Mindful
State University of New York at Buffalo
Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
08/22
08/22
Rosenthal, Philip
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
TRIUMPH, NCT04862221: TReatment for ImmUne Mediated PathopHysiology

Recruiting
2
163
US
High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
01/26
01/27
DRUMARS, NCT04969185: Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention

Completed
N/A
310
RoW
University of California, San Francisco, Institut de Recherche en Sciences de la Sante, Burkina Faso
Malaria,Falciparum
11/21
05/23
Cree, Bruce
IMPACT MS, NCT04466150: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Active, not recruiting
4
30
US
Ocrelizumab, Ocrevus
University of California, San Francisco, Genentech, Inc., Valhalla Foundation
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
12/26
07/27
NCT06451159: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Recruiting
1
10
US
KYV-101 (Biological) - 0.33 ×10^8 cells, CAR T-cell therapy, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
Bruce Cree, Kyverna Therapeutics
Progressive Multiple Sclerosis
06/26
06/27
Rosenthal, Phillip
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Active, not recruiting
3
254
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo, an Ipsen Company
Biliary Atresia
06/26
07/26
NCT03115086: The REPLACE Registry for Cholbam® (Cholic Acid)

Active, not recruiting
N/A
55
US
Cholbam
Mirum Pharmaceuticals, Inc.
Bile Acid Synthesis Disorders
07/38
07/39
Heyman, Melvin
CAMEO, NCT05781152: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Recruiting
4
900
Canada, US
Anti-TNF therapy, Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio
Connecticut Children's Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emory University, Children's Hospital Medical Center, Cincinnati, University of North Carolina, Chapel Hill
Crohn Disease
07/28
07/29
PAZAZ, NCT04186247: Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Completed
2
12
Europe, Canada, US, RoW
Azithromycin, Zithromax, Zmax, Metronidazole, Flagyl, Standard of Care
University of North Carolina, Chapel Hill, Crohn's and Colitis Foundation, University of Amsterdam
Crohn Disease, Pediatric Crohns Disease
12/23
12/23
Langlois, Camille
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
NCT05272319: Genetic Collection Protocol

Recruiting
N/A
2230
Canada, US
Arbor Research Collaborative for Health
Liver Diseases
05/29
05/29
Smith, Sara
STROBE, NCT05664516: A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder

Recruiting
2
60
US
TNX-1900 (Tonix Pharmaceuticals), Placebo
Massachusetts General Hospital
Binge-eating Disorder
04/24
04/24
NCT05598736: Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain

Enrolling by invitation
N/A
60
Europe
FlowOx 2.0
Otivio AS
Multiple Sclerosis, Spasticity, Muscle, Pain
06/23
12/23
FO-NP002, NCT05562453: Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain

Active, not recruiting
N/A
56
Europe
FlowOx 2.0, Intermittent negative pressure (Active), FlowOx2.0 (Sham), Intermittent negative pressure (Sham)
Otivio AS
Multiple Sclerosis, Spasticity, Muscle, Pain, Chronic
07/23
08/23
DTU-STEMI, NCT03947619: Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: the STEMI-DTU Trial

Active, not recruiting
N/A
527
Europe, Canada, US
Impella CP® placement prior to reperfusion with Primary PCI
Abiomed Inc.
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
09/24
10/30
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
Lincoln, Robin
NCT06451159: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Recruiting
1
10
US
KYV-101 (Biological) - 0.33 ×10^8 cells, CAR T-cell therapy, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
Bruce Cree, Kyverna Therapeutics
Progressive Multiple Sclerosis
06/26
06/27

Download Options